MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, NRXPW made $1,225K in revenue. -$28,622K in net income. Net profit margin of -2336.49%.

Income Overview

Revenue
$1,225K
Net Income
-$28,622K
Net Profit Margin
-2336.49%
Unit: Thousand (K) dollars
Revenue Breakdown
    • Therapy
    • Procedures
Revenue Breakdown
    • Commercial Insurance
    • Self Pay
    • Medicare

Income Statement
2025-12-31
Net patient service revenue
1,225
Cost of patient services
505
Research and development
3,777
Selling, general and administrative
13,061
Depreciation and amortization
70
Settlement expense (income)
36
Total operating expenses
17,449
Loss from operations
-16,224
Interest income
12
Interest expense
671
Change in fair value of convertible notes payable
3,939
Change in fair value of warrant liabilities
4,926
Loss on issuance of registered direct offering
-730
Loss on consideration shares and warrants
-1,277
Convertible note default penalty
0
Loss on convertible note conversions
-6,201
Loss from equity method investments
-35
Gain on exercise of warrants
5,369
Total other expense, net
-12,398
Net loss
-28,622
Basic EPS
-1.34
Basic Average Shares
21,401,683
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Net loss-$28,622K Therapy$854K Procedures$371K Loss from operations-$16,224K Total other expense,net-$12,398K Net patient servicerevenue$1,225K Gain on exercise ofwarrants$5,369K Interest income$12K Total operatingexpenses$17,449K Loss on convertiblenote conversions-$6,201K Change in fair value ofwarrant liabilities$4,926K Change in fair value ofconvertible notes payable$3,939K Loss onconsideration shares and...-$1,277K Loss on issuance ofregistered direct offering-$730K Interest expense$671K Loss from equitymethod investments-$35K Selling, general andadministrative$13,061K Research and development$3,777K Cost of patientservices$505K Depreciation andamortization$70K Settlement expense(income)$36K

NRX Pharmaceuticals, Inc. (NRXPW)

NRX Pharmaceuticals, Inc. (NRXPW)